New daratumumab data confirm huge potential
![Foto: Genmab, PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article5824812.ece/ALTERNATES/schema-16_9/Genmab_silver_on_green_sideview.jpg)
New England Journal of Medicine (NEJM) has published the full data set from the initial Phase I/II study with daratumumab monotherapy treating patients with relapsed or refractory multiple myeloma, Denmark’s Genmab said last week.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analyst: Genmab hope could hit the market this year
For abonnenter
Genmab and Novo team up in massive new deal
For abonnenter
Genmab CEO considers new acquisitions
For abonnenter